Interview: Eucope On Turning Ten, Defending Orphan Incentives And Securing Market Access For Cell And Gene Therapies
Executive Summary
Ten years on from its inception, the European Confederation of Pharmaceutical Entrepreneurs is focused on defending the incentives system for developing orphan drugs.
You may also be interested in...
More Checks And Balances For Orphan Drugs Needed, Says Germany’s G-BA
The German pricing and reimbursement authority wants better scrutiny of orphan drug designations and incentives for orphan drug development to help address the access problem.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.